US 12,398,420 B2
Compositions to detect adenovirus nucleic acids
Mehrdad R. Majlessi, Escondido, CA (US); Ankur Shah, San Diego, CA (US); Amber Hillius, San Diego, CA (US); Pamela Douglass, Kansas City, MO (US); and Daniel Kolk, Ramona, CA (US)
Assigned to GEN-PROBE INCORPORATED, San Diego, CA (US)
Filed by Gen-Probe Incorporated, San Diego, CA (US)
Filed on Dec. 27, 2022, as Appl. No. 18/146,589.
Application 18/146,589 is a continuation of application No. 17/820,256, filed on Aug. 17, 2022.
Application 17/820,256 is a continuation of application No. 17/834,578, filed on Jun. 7, 2022.
Application 17/834,578 is a continuation of application No. 16/497,229, granted, now 11,384,387, issued on Jul. 12, 2022, previously published as PCT/US2018/024141, filed on Mar. 23, 2018.
Claims priority of provisional application 62/476,753, filed on Mar. 25, 2017.
Prior Publication US 2023/0203572 A1, Jun. 29, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6844 (2018.01); C12Q 1/70 (2006.01)
CPC C12Q 1/6844 (2013.01) [C12Q 1/701 (2013.01); C12Q 2600/16 (2013.01)] 21 Claims
 
1. A composition for determining the presence or absence of an Adenovirus target nucleic acid in a sample, the composition comprising:
a first amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:71, 72, 73, and 74;
a second amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:61 and 62; and
at least one additional amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:61, 62, 71, 72, 73, and 74, wherein the at least one additional amplification oligomers is different from the first amplification oligomer and the second amplification oligomer.